This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Asia Bio Partnering Forum
Marina Bay Sands Convention Center
April 24—25, 2024 | SingaporeApril 29—30, 2024 | Virtual

BiotechPharma Corp


Biotech Pharma, Inc., (BTP) has developed a “Split Sample” platform for body fluids collection and liquid biopsy test kits. The first-generation devices are called DRG-8260 (also known as EZ-SALIVA I) and EZ-SALIVA II. The platform utilizes a “Split” sample qualitative/quantitative rapid immunoassay test strips for point of care testing for toxicology, disease detection and health screening. The rapid test strips used in the collection devices are either FDA approved for forensic use (lab use only) or are CE Marked and/or CFDA approved. The BTP EZ-SALIVA II collection device test kits include a split sample feature for laboratory confirmation or additional testing if needed. This patented split sample technology sequesters part of the original body fluid sample at the time of collection into a separate built-in lab vial. This vial can then be inserted into a standard lab analyzer to determine a quantitative confirmation of any positive results or additional testing as indicated by the qualitative rapid strips.